Skip to main
SNN
SNN logo

SNN Stock Forecast & Price Target

SNN Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 0%
Buy 25%
Hold 75%
Sell 0%
Strong Sell 0%

Bulls say

The financial performance of Smith & Nephew shows promising trends, particularly with an underlying growth rate of +5.3% and a significant increase in the orthopedic segment, which generated +5.5% reported growth, showcasing strong US sales despite challenges in the international market. The company has noted impressive expansion in its enabling technology, particularly with a 23.9% increase in Other Reconstruction revenues attributed to the success of the CORI system, indicating a solid foothold in the knee procedure market. Furthermore, the forecast for 2025 suggests sustained growth of approximately 5%, along with an expected trading profit margin between 19.0% and 20.0%, reinforcing a positive long-term outlook for Smith & Nephew.

Bears say

Smith & Nephew's revenue guidance for FY25 suggests a weaker performance in Q1, attributed to factors such as fewer selling days and continued distributor inventory impacts in China. The company anticipates additional negative revenue impacts from value-based pricing (VBP) adjustments, particularly in its Advanced Wound Therapy segment, amounting to $25 million in the second half of 2025. Additionally, while the Orthopedic segment has achieved positive return on invested capital (ROIC), it remains significantly lower compared to the company's other segments, coupled with challenges stemming from the evolving US healthcare landscape and ongoing headwinds in emerging markets like China.

SNN has been analyzed by 4 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 25% recommend Buy, 75% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Smith & Nephew and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Smith & Nephew (SNN) Forecast

Analysts have given SNN a Hold based on their latest research and market trends.

According to 4 analysts, SNN has a Hold consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Smith & Nephew (SNN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.